Literature DB >> 20100989

Receptor activity-modifying protein 1 increases baroreflex sensitivity and attenuates Angiotensin-induced hypertension.

Rasna Sabharwal1, Zhongming Zhang, Yongjun Lu, Francois M Abboud, Andrew F Russo, Mark W Chapleau.   

Abstract

Calcitonin gene-related peptide (CGRP) is a powerful vasodilator that interacts with the autonomic nervous system. A subunit of the CGRP receptor complex, receptor activity-modifying protein 1 (RAMP1), is required for trafficking of the receptor to the cell surface and high-affinity binding to CGRP. We hypothesized that upregulation of RAMP1 would favorably enhance autonomic regulation and attenuate hypertension. Blood pressure, heart rate, and locomotor activity were measured by radiotelemetry in transgenic mice with ubiquitous expression of human RAMP1 (hRAMP1) and littermate controls. Compared with control mice, hRAMP1 mice exhibited similar mean arterial pressure, a lower mean heart rate, increased heart rate variability, reduced blood pressure variability, and increased baroreflex sensitivity (2.83+/-0.20 versus 1.49+/-0.10 ms/mm Hg in controls; P<0.05). In control mice, infusion of angiotensin II (Ang-II) increased mean arterial pressure from 118+/-2 mm Hg to 153+/-4 and 174+/-6 mm Hg after 7 and 14 days of infusion, respectively (P<0.05). In contrast, Ang-II hypertension was markedly attenuated in hRAMP1 mice with corresponding values of mean arterial pressure of 111+/-2, 119+/-2, and 132+/-3 mm Hg. Ang-II induced decreases in baroreflex sensitivity and heart rate variability, and increases in blood pressure variability observed in control mice were also abrogated or reversed in hRAMP1 mice (P<0.05). Moreover, during the Ang-II infusion, the pressor response to the CGRP receptor antagonist CGRP(8-37) was significantly greater (P<0.05) in hRAMP1 mice (+30+/-2 mm Hg) than in control mice (+19+/-2 mm Hg), confirming a significantly greater antihypertensive action of endogenous CGRP in hRAMP1 mice. We conclude that RAMP1 overexpression attenuates Ang-II-induced hypertension and induces a protective change in cardiovascular autonomic regulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20100989      PMCID: PMC2902886          DOI: 10.1161/HYPERTENSIONAHA.109.148171

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  48 in total

1.  Effects of CGRP on baroreflex control of heart rate and renal sympathetic nerve activity in rabbits.

Authors:  H Okamoto; S Hoka; T Kawasaki; M Sato; J Yoshitake
Journal:  Am J Physiol       Date:  1992-10

Review 2.  Systemic arterial baroreceptor reflexes.

Authors:  H R Kirchheim
Journal:  Physiol Rev       Date:  1976-01       Impact factor: 37.312

3.  Retrograde neuronal labelling and double-staining immunohistochemistry of tachykinin- and calcitonin gene-related peptide-immunoreactive pathways in the carotid sinus nerve of the guinea pig.

Authors:  W Kummer
Journal:  J Auton Nerv Syst       Date:  1988-08

4.  Autoradiographic localization of calcitonin gene-related peptide binding sites in human and rat brains.

Authors:  S Inagaki; S Kito; Y Kubota; S Girgis; C J Hillyard; I MacIntyre
Journal:  Brain Res       Date:  1986-05-28       Impact factor: 3.252

5.  Central cardiovascular effects of calcitonin gene-related peptide: interaction with noradrenaline in the nucleus tractus solitarius of rats.

Authors:  M Vallejo; S Lightman; I Marshall
Journal:  Exp Brain Res       Date:  1988       Impact factor: 1.972

6.  Microinjection of alpha-calcitonin gene-related peptide into the hypothalamus activates sympathetic outflow in rats.

Authors:  T Hasegawa; K Yokotani; Y Okuma; M Manabe; M Hirakawa; Y Osumi
Journal:  Jpn J Pharmacol       Date:  1993-04

7.  Area postrema is critical for angiotensin-induced hypertension in rats.

Authors:  G D Fink; C A Bruner; M L Mangiapane
Journal:  Hypertension       Date:  1987-04       Impact factor: 10.190

8.  Calcitonin gene-related peptide: detailed immunohistochemical distribution in the central nervous system.

Authors:  G Skofitsch; D M Jacobowitz
Journal:  Peptides       Date:  1985 Jul-Aug       Impact factor: 3.750

9.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

Authors:  Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner
Journal:  Lancet       Date:  2008-11-25       Impact factor: 79.321

10.  Modulatory effect of the renin-angiotensin system on the plasma levels of calcitonin gene-related peptide in normal man.

Authors:  F Portaluppi; L Vergnani; A Margutti; M R Ambrosio; M Bondanelli; G Trasforini; R Rossi; E C Degli Uberti
Journal:  J Clin Endocrinol Metab       Date:  1993-09       Impact factor: 5.958

View more
  25 in total

Review 1.  Sleep apnea, cardiac arrhythmias, and sudden death.

Authors:  Ondrej Ludka; Tomas Konecny; Virend Somers
Journal:  Tex Heart Inst J       Date:  2011

2.  CGRP receptor activity in mice with global expression of human receptor activity modifying protein 1.

Authors:  Keegan J Bohn; Baolin Li; Xiaofang Huang; Bianca N Mason; Anne-Sophie Wattiez; Adisa Kuburas; Christopher S Walker; Peiyi Yang; Jianliang Yu; Beverly A Heinz; Kirk W Johnson; Andrew F Russo
Journal:  Br J Pharmacol       Date:  2017-04-22       Impact factor: 8.739

Review 3.  CGRP as a neuropeptide in migraine: lessons from mice.

Authors:  Andrew F Russo
Journal:  Br J Clin Pharmacol       Date:  2015-07-14       Impact factor: 4.335

Review 4.  Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles.

Authors:  Debbie L Hay; Augen A Pioszak
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

5.  Chronic oral administration of Ang-(1-7) improves skeletal muscle, autonomic and locomotor phenotypes in muscular dystrophy.

Authors:  Rasna Sabharwal; Michael Z Cicha; Ruben D M Sinisterra; Frederico B De Sousa; Robson A Santos; Mark W Chapleau
Journal:  Clin Sci (Lond)       Date:  2014-07       Impact factor: 6.124

Review 6.  Understanding RAMPs through genetically engineered mouse models.

Authors:  Mahita Kadmiel; Kimberly L Fritz-Six; Kathleen M Caron
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 7.  Methods of assessing vagus nerve activity and reflexes.

Authors:  Mark W Chapleau; Rasna Sabharwal
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

8.  Receptor activity-modifying protein-1 augments cerebrovascular responses to calcitonin gene-related peptide and inhibits angiotensin II-induced vascular dysfunction.

Authors:  Sophocles Chrissobolis; Zhongming Zhang; Dale A Kinzenbaw; Cynthia M Lynch; Andrew F Russo; Frank M Faraci
Journal:  Stroke       Date:  2010-09-02       Impact factor: 7.914

9.  RAMP1 is a direct NKX3.1 target gene up-regulated in prostate cancer that promotes tumorigenesis.

Authors:  Monica Logan; Philip D Anderson; Shahrazad T Saab; Omar Hameed; Sarki A Abdulkadir
Journal:  Am J Pathol       Date:  2013-07-16       Impact factor: 4.307

10.  Calcitonin gene-related peptide (CGRP) in autonomic cardiovascular regulation and vascular structure.

Authors:  Tu H Mai; Jing Wu; André Diedrich; Emily M Garland; David Robertson
Journal:  J Am Soc Hypertens       Date:  2014-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.